Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Frequently asked questions
What sector does Enliven Therapeutics Inc. (ELVN) operate in?
Enliven Therapeutics Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Enliven Therapeutics Inc. (ELVN) current stock price?
As of the latest data, Enliven Therapeutics Inc. stock price is $41.49, with a previous close of $41.52. Enliven Therapeutics Inc. lost -$0.03 in the last trading session, representing a -0.07% loss.
What is Enliven Therapeutics Inc. (ELVN) current market capitalization?
Enliven Therapeutics Inc. market cap is approximately 3.04 billion.
What is Enliven Therapeutics Inc. (ELVN) Earnings Per Share (EPS)?
The trailing EPS is -$1.61, and the forward EPS is -$2.34.
What is Enliven Therapeutics Inc. (ELVN) EBITDA?
Enliven Therapeutics Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -32.48 million.
Does Enliven Therapeutics Inc. (ELVN) pay dividends?
No. Enliven Therapeutics Inc. does not pay a dividend.
What is Enliven Therapeutics Inc. (ELVN) beta (volatility) score?
Enliven Therapeutics Inc. has a beta of 0.245, indicating lower volatility than the overall market.
